ZA200206764B - Orally administered controlled delivery system for once daily administration of ciprofloxacin. - Google Patents
Orally administered controlled delivery system for once daily administration of ciprofloxacin. Download PDFInfo
- Publication number
- ZA200206764B ZA200206764B ZA200206764A ZA200206764A ZA200206764B ZA 200206764 B ZA200206764 B ZA 200206764B ZA 200206764 A ZA200206764 A ZA 200206764A ZA 200206764 A ZA200206764 A ZA 200206764A ZA 200206764 B ZA200206764 B ZA 200206764B
- Authority
- ZA
- South Africa
- Prior art keywords
- formulation
- ciprofloxacin
- agent
- xanthan gum
- sodium alginate
- Prior art date
Links
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 title claims description 171
- 229960003405 ciprofloxacin Drugs 0.000 title claims description 88
- 239000003826 tablet Substances 0.000 claims description 133
- 239000000203 mixture Substances 0.000 claims description 119
- 239000003814 drug Substances 0.000 claims description 81
- 238000009472 formulation Methods 0.000 claims description 76
- 239000003795 chemical substances by application Substances 0.000 claims description 72
- 229940079593 drug Drugs 0.000 claims description 68
- 229920001285 xanthan gum Polymers 0.000 claims description 40
- 235000010493 xanthan gum Nutrition 0.000 claims description 40
- 239000000230 xanthan gum Substances 0.000 claims description 40
- 229940082509 xanthan gum Drugs 0.000 claims description 40
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical group CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 39
- 235000010413 sodium alginate Nutrition 0.000 claims description 39
- 239000000661 sodium alginate Substances 0.000 claims description 39
- 229940005550 sodium alginate Drugs 0.000 claims description 39
- 230000008961 swelling Effects 0.000 claims description 34
- 239000003349 gelling agent Substances 0.000 claims description 32
- 239000004615 ingredient Substances 0.000 claims description 26
- 239000002775 capsule Substances 0.000 claims description 21
- 210000002966 serum Anatomy 0.000 claims description 21
- 210000002784 stomach Anatomy 0.000 claims description 21
- 230000036470 plasma concentration Effects 0.000 claims description 18
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 17
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 17
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 17
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 14
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 14
- 238000013270 controlled release Methods 0.000 claims description 12
- 230000002401 inhibitory effect Effects 0.000 claims description 11
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 10
- 238000013268 sustained release Methods 0.000 claims description 10
- 239000012730 sustained-release form Substances 0.000 claims description 10
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 8
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 8
- 150000001720 carbohydrates Chemical class 0.000 claims description 8
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 8
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 8
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 8
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 8
- 239000007909 solid dosage form Substances 0.000 claims description 8
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 7
- 210000000813 small intestine Anatomy 0.000 claims description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 6
- 229920003086 cellulose ether Polymers 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- 239000007916 tablet composition Substances 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 5
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 4
- 229920003091 Methocel™ Polymers 0.000 claims description 3
- 239000002356 single layer Substances 0.000 claims 2
- 238000004090 dissolution Methods 0.000 description 39
- 239000007789 gas Substances 0.000 description 37
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 34
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 34
- 238000012377 drug delivery Methods 0.000 description 30
- 239000000599 controlled substance Substances 0.000 description 25
- 239000008194 pharmaceutical composition Substances 0.000 description 21
- 239000011159 matrix material Substances 0.000 description 20
- 238000010521 absorption reaction Methods 0.000 description 18
- 239000002585 base Substances 0.000 description 18
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 18
- 235000017557 sodium bicarbonate Nutrition 0.000 description 18
- 239000004480 active ingredient Substances 0.000 description 17
- 235000019359 magnesium stearate Nutrition 0.000 description 17
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 17
- 230000001186 cumulative effect Effects 0.000 description 16
- 230000002496 gastric effect Effects 0.000 description 16
- 239000012530 fluid Substances 0.000 description 15
- 210000001035 gastrointestinal tract Anatomy 0.000 description 12
- 235000002639 sodium chloride Nutrition 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000000314 lubricant Substances 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- 239000008187 granular material Substances 0.000 description 8
- 230000000717 retained effect Effects 0.000 description 8
- 239000000454 talc Substances 0.000 description 8
- 229910052623 talc Inorganic materials 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 230000014759 maintenance of location Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 230000003466 anti-cipated effect Effects 0.000 description 6
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 6
- 239000000227 bioadhesive Substances 0.000 description 6
- 235000021152 breakfast Nutrition 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- 235000015165 citric acid Nutrition 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 229920002785 Croscarmellose sodium Polymers 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 239000007884 disintegrant Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- -1 e.g. Polymers 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 150000007524 organic acids Chemical class 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 230000036765 blood level Effects 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 4
- 239000008279 sol Substances 0.000 description 4
- 230000002123 temporal effect Effects 0.000 description 4
- 229920003094 Methocel™ K4M Polymers 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- DIOIOSKKIYDRIQ-UHFFFAOYSA-N ciprofloxacin hydrochloride Chemical group Cl.C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 DIOIOSKKIYDRIQ-UHFFFAOYSA-N 0.000 description 3
- 229960001229 ciprofloxacin hydrochloride Drugs 0.000 description 3
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000008199 coating composition Substances 0.000 description 2
- 238000005056 compaction Methods 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 235000020937 fasting conditions Nutrition 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000001630 jejunum Anatomy 0.000 description 2
- 239000007942 layered tablet Substances 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 2
- 239000004584 polyacrylic acid Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 239000004408 titanium dioxide Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- JVTIXNMXDLQEJE-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate 2-octanoyloxypropyl octanoate Chemical compound C(CCCCCCC)(=O)OCC(C)OC(CCCCCCC)=O.C(=O)(CCCCCCCCC)OCC(C)OC(=O)CCCCCCCCC JVTIXNMXDLQEJE-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 240000004181 Eucalyptus cladocalyx Species 0.000 description 1
- 241000828585 Gari Species 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 229920003095 Methocel™ K15M Polymers 0.000 description 1
- 101100256746 Mus musculus Setdb1 gene Proteins 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 238000006935 Simonis synthesis reaction Methods 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241000949477 Toona ciliata Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241000589636 Xanthomonas campestris Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000010564 aerobic fermentation Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000011692 calcium ascorbate Substances 0.000 description 1
- 235000010376 calcium ascorbate Nutrition 0.000 description 1
- 229940047036 calcium ascorbate Drugs 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940031304 ciprofloxacin 1000 mg Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000013267 controlled drug release Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 101150007515 esr2 gene Proteins 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940085942 formulation r Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 239000011346 highly viscous material Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000002706 hydrostatic effect Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51788700A | 2000-03-03 | 2000-03-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200206764B true ZA200206764B (en) | 2003-03-04 |
Family
ID=24061635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200206764A ZA200206764B (en) | 2000-03-03 | 2002-08-23 | Orally administered controlled delivery system for once daily administration of ciprofloxacin. |
Country Status (31)
| Country | Link |
|---|---|
| EP (1) | EP1263409A1 (ja) |
| JP (1) | JP2003525229A (ja) |
| KR (1) | KR20030009374A (ja) |
| CN (1) | CN1420763A (ja) |
| AP (2) | AP2001002084A0 (ja) |
| AR (1) | AR032614A1 (ja) |
| AU (1) | AU3589701A (ja) |
| BG (1) | BG107055A (ja) |
| BR (1) | BR0108958A (ja) |
| CA (1) | CA2400950A1 (ja) |
| CZ (1) | CZ20022883A3 (ja) |
| DO (1) | DOP2001000130A (ja) |
| EA (1) | EA200200914A1 (ja) |
| EC (1) | ECSP013952A (ja) |
| EE (1) | EE200200497A (ja) |
| GT (1) | GT200100033A (ja) |
| HN (1) | HN2001000038A (ja) |
| HR (1) | HRP20020715A2 (ja) |
| HU (1) | HUP0204417A3 (ja) |
| IL (1) | IL151553A0 (ja) |
| IS (1) | IS6532A (ja) |
| MX (1) | MXPA02008568A (ja) |
| NO (1) | NO20024108L (ja) |
| NZ (1) | NZ520927A (ja) |
| OA (1) | OA12381A (ja) |
| PE (1) | PE20011113A1 (ja) |
| PL (1) | PL365071A1 (ja) |
| SK (1) | SK12542002A3 (ja) |
| WO (1) | WO2001064183A1 (ja) |
| YU (1) | YU66202A (ja) |
| ZA (1) | ZA200206764B (ja) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
| US20030229101A1 (en) * | 2002-06-06 | 2003-12-11 | Sherman Bernard Charles | Tablets comprising ciprofloxacin hydrochloride |
| DE10351448A1 (de) | 2003-11-04 | 2005-06-09 | Bayer Healthcare Ag | Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften |
| EP1745775B1 (en) * | 2005-07-19 | 2008-05-28 | Ethypharm | Gastroretentive formulations and manufacturing process thereof. |
| EP1880722B1 (en) * | 2006-07-19 | 2010-03-17 | Tabuk Pharmaceutical Manufacturing Co. | Pharmaceutical compositions of ciprofloxacin |
| WO2016115253A1 (en) | 2015-01-14 | 2016-07-21 | The Regents Of The University Ofcolordo, A Body Corporate | Insulin mimotopes and methods of using the same |
| EP3419669A4 (en) * | 2016-02-23 | 2019-10-30 | Matripharm International Inc. | DOUBLE-SPEED RELEASE COMPOSITION WITH HIGH MEDICAL DRUG CHARGE |
| AU2017236977B2 (en) | 2016-03-24 | 2022-05-26 | Immunomolecular Therapeutics, Inc. | Methods of treating autoimmune disease |
| US11052060B2 (en) | 2018-02-12 | 2021-07-06 | The Regents Of The University Of Colorado, A Body Corporate | Compounds and methods for treating autoimmunity |
| US11013707B2 (en) | 2018-03-23 | 2021-05-25 | The Regents Of The University Of Colorado, A Body Corporate | Administration of oral methyldopa |
| CN109806237A (zh) * | 2019-03-13 | 2019-05-28 | 悦康药业集团上海制药有限公司 | 一种乳酸环丙沙星泡腾片及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5096714A (en) * | 1988-06-28 | 1992-03-17 | Hauser-Kuhrts, Inc. | Prolonged release drug tablet formulations |
| JPH0624959A (ja) * | 1991-10-04 | 1994-02-01 | Bayer Yakuhin Kk | 胃内浮遊型薬物徐放性固形製剤 |
| DE4406424A1 (de) * | 1994-02-28 | 1995-08-31 | Bayer Ag | Expandierbare Arzneiformen |
| DE19839057A1 (de) * | 1998-08-28 | 2000-03-02 | Koch Berthold | Spülluft-Regler für eine Trockenvorrichtung für Druckluft |
| EA004443B1 (ru) * | 1998-09-14 | 2004-04-29 | Рэнбакси Лабораториз Лимитед | Лекарственная форма для контролируемого высвобождения ципрофлоксацина для приема один раз в день |
-
2001
- 2001-02-28 WO PCT/IB2001/000279 patent/WO2001064183A1/en not_active Application Discontinuation
- 2001-02-28 AP APAP/P/2001/002084A patent/AP2001002084A0/en unknown
- 2001-02-28 CZ CZ20022883A patent/CZ20022883A3/cs unknown
- 2001-02-28 AR ARP010100957A patent/AR032614A1/es not_active Application Discontinuation
- 2001-02-28 AU AU35897/01A patent/AU3589701A/en not_active Abandoned
- 2001-02-28 HU HU0204417A patent/HUP0204417A3/hu unknown
- 2001-02-28 CA CA002400950A patent/CA2400950A1/en not_active Abandoned
- 2001-02-28 CN CN01805998A patent/CN1420763A/zh active Pending
- 2001-02-28 SK SK1254-2002A patent/SK12542002A3/sk unknown
- 2001-02-28 PL PL01365071A patent/PL365071A1/xx not_active Application Discontinuation
- 2001-02-28 OA OA1200200267A patent/OA12381A/en unknown
- 2001-02-28 AP APAP/P/2002/002627A patent/AP1485A/en active
- 2001-02-28 EP EP01908038A patent/EP1263409A1/en not_active Withdrawn
- 2001-02-28 YU YU66202A patent/YU66202A/sh unknown
- 2001-02-28 JP JP2001563081A patent/JP2003525229A/ja not_active Withdrawn
- 2001-02-28 EE EEP200200497A patent/EE200200497A/xx unknown
- 2001-02-28 KR KR1020027011441A patent/KR20030009374A/ko not_active Application Discontinuation
- 2001-02-28 MX MXPA02008568A patent/MXPA02008568A/es unknown
- 2001-02-28 IL IL15155301A patent/IL151553A0/xx unknown
- 2001-02-28 BR BR0108958-7A patent/BR0108958A/pt not_active Withdrawn
- 2001-02-28 NZ NZ520927A patent/NZ520927A/xx unknown
- 2001-02-28 EA EA200200914A patent/EA200200914A1/ru unknown
- 2001-03-01 EC EC2001003952A patent/ECSP013952A/es unknown
- 2001-03-01 GT GT200100033A patent/GT200100033A/es unknown
- 2001-03-01 PE PE2001000206A patent/PE20011113A1/es not_active Application Discontinuation
- 2001-03-02 HN HN2001000038A patent/HN2001000038A/es unknown
- 2001-03-02 DO DO2001000130A patent/DOP2001000130A/es unknown
-
2002
- 2002-08-23 ZA ZA200206764A patent/ZA200206764B/en unknown
- 2002-08-28 IS IS6532A patent/IS6532A/is unknown
- 2002-08-28 NO NO20024108A patent/NO20024108L/no unknown
- 2002-08-30 HR HRP20020715 patent/HRP20020715A2/hr not_active Application Discontinuation
- 2002-09-02 BG BG107055A patent/BG107055A/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| OA12381A (en) | 2004-09-06 |
| CZ20022883A3 (cs) | 2003-04-16 |
| KR20030009374A (ko) | 2003-01-29 |
| WO2001064183A1 (en) | 2001-09-07 |
| IS6532A (is) | 2002-08-28 |
| EP1263409A1 (en) | 2002-12-11 |
| CN1420763A (zh) | 2003-05-28 |
| HN2001000038A (es) | 2005-03-23 |
| NO20024108D0 (no) | 2002-08-28 |
| AU3589701A (en) | 2001-09-12 |
| BG107055A (bg) | 2003-06-30 |
| MXPA02008568A (es) | 2003-02-24 |
| HRP20020715A2 (en) | 2004-12-31 |
| AP2002002627A0 (en) | 2002-09-30 |
| IL151553A0 (en) | 2003-04-10 |
| PL365071A1 (en) | 2004-12-27 |
| AP1485A (en) | 2005-10-31 |
| NO20024108L (no) | 2002-10-25 |
| GT200100033A (es) | 2001-10-25 |
| HUP0204417A2 (en) | 2003-05-28 |
| AR032614A1 (es) | 2003-11-19 |
| CA2400950A1 (en) | 2001-09-07 |
| PE20011113A1 (es) | 2001-10-14 |
| YU66202A (sh) | 2005-09-19 |
| EA200200914A1 (ru) | 2003-02-27 |
| BR0108958A (pt) | 2003-09-30 |
| HUP0204417A3 (en) | 2005-03-29 |
| NZ520927A (en) | 2003-06-30 |
| DOP2001000130A (es) | 2004-03-31 |
| SK12542002A3 (sk) | 2003-05-02 |
| JP2003525229A (ja) | 2003-08-26 |
| AP2001002084A0 (en) | 2001-03-31 |
| EE200200497A (et) | 2004-02-16 |
| ECSP013952A (es) | 2002-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6261601B1 (en) | Orally administered controlled drug delivery system providing temporal and spatial control | |
| EP1107741B1 (en) | Orally administered controlled drug delivery system providing temporal and spatial control | |
| US6899896B2 (en) | Hydrogel-driven layered drug dosage form | |
| EP1750717B1 (en) | Controlled release pharmaceutical compositions with improved bioavailability | |
| WO2002017885A2 (en) | Controlled release formulation of erythromycin or a derivative thereof | |
| US20020119192A1 (en) | Controlled release formulations for oral administration | |
| ZA200206764B (en) | Orally administered controlled delivery system for once daily administration of ciprofloxacin. | |
| AU2006201553A1 (en) | Orally administered controlled delivery system for once daily administration of ciprofloxacin | |
| EP3087978A1 (en) | Sustained-release pharmaceutical composition containing acebrophylline and hydrophillic sustained-release agent | |
| EP4373474A1 (en) | Bilayer tablet comprising telmisartan and indapamide | |
| US20080206338A1 (en) | Controlled release formulations of an alpha-adrenergic receptor antagonist | |
| WO2024165966A1 (en) | Gastroretentive extended release compositions of riociguat | |
| KR20210157692A (ko) | 다비가트란 에텍실레이트를 포함하는 경구용 약학조성물 | |
| WO2008050188A2 (en) | Sustained release pharmaceutical compositions of alfuzosin and process for preparation thereof |